Efficacy of oral selective estrogen receptor degraders (SERD)s in the treatment of estrogen receptor positive (ER+), HER2-negative metastatic breast cancer (MBC): A stratified analysis of the ESR1 wild type (wt) and mutant (mt) subgroups.
Zhao J, Wong Zhun Hong N, Yap D, Ong R, Sundar R, Lim J, Dawood S. Efficacy of oral selective estrogen receptor degraders (SERD)s in the treatment of estrogen receptor positive (ER+), HER2-negative metastatic breast cancer (MBC): A stratified analysis of the ESR1 wild type (wt) and mutant (mt) subgroups. Journal Of Clinical Oncology 2023, 41: 1096-1096. DOI: 10.1200/jco.2023.41.16_suppl.1096.Peer-Reviewed Original ResearchProgression free survival benefitTreatment of physician's choiceProgression free survivalMetastatic breast cancerEndocrine therapyESR1 mutationsOverall cohortEstrogen receptorKaplan MeierEstimate time-to-event outcomesHER2-negative metastatic breast cancerOral selective estrogen receptor degraderHER2- metastatic breast cancerSurvival dataTreatment of estrogen receptorSelective estrogen receptor degraderOverall populationCompare survival outcomesIPD meta-analysisMeta-analysisEstrogen receptor degraderOral SERDsPFS differenceCompared to ETFree survival